Published/Forthcoming Work:

Due, A. Forthcoming. “Is There a ‘Best’ Way for the Public to Participate in Pharmacovigilance?” Journal of Medicine and Philosophy. Pre-print here.

Due, A. 2024. “Sins and Risks in Underreporting Suspected Adverse Drug Reactions.” Philosophy of Medicine 5.1. https://doi.org/10.5195/pom.2024.181. Pre-print available here.

Due, A. 2023. “What are Side Effects?” European Journal for Philosophy of Science 13.1. https://doi.org/10.1007/s13194-023-00519-8. Pre-print here.

Due, A. 2022. “Are ‘Phase IV’ Trials Exploratory or Confirmatory Experiments?” Studies in History and Philosophy of Science 95, 126-133. https://doi.org/10.1016/j.shpsa.2022.07.006. Pre-print here.

Work Under Review:

“Patient Participation & Empowerment in Precision Medicine.” Manuscript available here.

“Noisy Nocebo Harms in Pharmacovigilance Data: A Two-Part Problem for Patient-Engaged Reporting.”

Works in Progress:

“Talk Therapy’s Adverse Events: Side Effects, Symptoms, or Something Else?”

Abstract: Like all medical interventions, talk therapies like cognitive behavioral therapy (CBT) are associated with adverse events. However, researchers have pointed out that we have a paucity of causal knowledge around psychiatric illnesses. Moreover, the causal capacities of something like CBT are unclear. Because of this, we are in an epistemic bind if we want to determine the side effects of these sorts of therapies, since determining side effects requires this kind of knowledge.

“Regulating Novel Technologies & Methods in Precision Agriculture: Lessons from Medicine.”

Abstract: Precision agriculture (which pre-dates precision medicine by over two decades) is often cashed out as a novel approach to farm management utilizing technologies like variable-rate application systems, machine learning, self-driving tractors, and the use of UAVs. The regulation of these technologies and methods is minimal, meaning that risks with adopting these practices (which are pushed by large, private agriculture companies) fall on individual farmers instead of companies that market them. I look to two analogs, (1) regulating novel medicines in precision medicine and (2) regulating techniques and procedures in surgery to draw some lessons for precision agriculture.

On the Horizon:

“Uninvited Participation for Scientific Objectivity.”

“Drugs, Crops, & Kinds.”

“The Land Ethic & Gentle Medicine.”

“Epistemic & Ethical Justifications for Radically Informed Consent.”